Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01108939
Other study ID # Fe_Malaria_Benin
Secondary ID
Status Completed
Phase Phase 0
First received April 21, 2010
Last updated June 6, 2013
Start date February 2009
Est. completion date April 2010

Study information

Verified date June 2013
Source Swiss Federal Institute of Technology
Contact n/a
Is FDA regulated No
Health authority Benin: Ministry of Health
Study type Interventional

Clinical Trial Summary

Anemia is still a main public health problem in sub-Saharan Africa. Anemic women have an increased maternal and perinatal mortality and anemic adults have diminished work capacity. In sub-Saharan Africa, the etiology of anemia is multifactoral; the major causes are low dietary bioavailability and chronic parasitic infections such as malaria. These causes are likely to interact because infection and infection-associated inflammation may impair the utilization and absorption of iron. Therefore, the control of parasite infections may be important to improve iron bioavailability from foods.

Malaria infections are endemic in northern Benin. To investigate the contribution of asymptomatic malaria (a positive blood smear for malarial parasites but without clinical symptoms of fever, headache or malaise) to anemia, we are planning a human iron absorption study in Benin. We will recruit adults with asymptomatic malaria infection. The iron absorption and utilization of the study subjects will be studied while infected, then they will be treated to clear their infections, and then iron absorption and utilization will be restudied. Iron absorption will be determined by incorporation of labeled iron into erythrocytes, 14 days after the administration of a test meal containing labeled iron (stable isotope technique). Subjects will be men and non-pregnant, non-breastfeeding women with a body weight < 65 kg and between the age of 18 - 30 years.

The results of this study will provide important information on the influence of malaria infections on iron absorption and utilization in humans. The study will provide insight into the potential necessity of malaria control to ensure iron bioavailability from foods in developing countries.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date April 2010
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender Female
Age group 16 Years to 35 Years
Eligibility Inclusion Criteria:

- Age 18-35 y

- Body weight < 65 kg

- A positive malaria smear (asexual P. falciparum parasitemia > 500/µL blood) without clinical symptoms (fever or self-reported fever in last 7 days, headache, malaise)

- If female, not pregnant (tested by pregnancy test) and not breastfeeding

- No mineral and vitamin supplements two weeks before and during the study

Exclusion Criteria:

- Severe anemia (hemoglobin < 8.0 g/dl)

- Chronic medical illnesses

- Blood donation or transfusion in the last 6 months before study time

- Soil-transmitted helminth infections (positive Kato-Katz-Smear)

- Tuberculosis (TB): The potential presence of TB will be excluded by a short health questionnaire (cough? night sweats? weight loss? close relative with TB?). If this questionnaire raises the possibility that the subject may be at risk for TB, he/she will be referred to the local medical service

Study Design

Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Antimalarial treatment

Other:
Observation


Locations

Country Name City State
Benin Hopital de zone de Natitingou Natitingou

Sponsors (2)

Lead Sponsor Collaborator
Swiss Federal Institute of Technology European Union

Country where clinical trial is conducted

Benin, 

See also
  Status Clinical Trial Phase
Completed NCT02329301 - Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia N/A
Recruiting NCT01944189 - Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Phase 4
Terminated NCT01442168 - Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria Phase 1/Phase 2
Completed NCT01325974 - Time to Become Negative of Three Rapid Diagnostic Tests for Malaria N/A
Terminated NCT00374205 - Randomized Trial on Effectiveness of ACTs in Ghana Phase 4
Completed NCT00375128 - Sporozoite Challenge of Polyprotein Vaccinees Phase 1/Phase 2
Completed NCT04609098 - Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) Phase 2
Completed NCT02851108 - Methylene Blue Against Falciparum Malaria in Burkina Faso Phase 2
Terminated NCT02281344 - MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants Phase 1
Completed NCT02434952 - Safety and Tolerability of Low Dose Primaquine Phase 4
Completed NCT01213966 - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection Phase 2
Completed NCT00479206 - Artemisinin Resistance in Cambodia N/A
Completed NCT00126906 - Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi N/A
Completed NCT01019408 - Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan Phase 4
Completed NCT00529867 - Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria Phase 4
Completed NCT00137553 - The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children Phase 4
Completed NCT02637128 - In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Phase 4
Completed NCT01222962 - Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers Phase 1
Unknown status NCT00152204 - The Community Effectiveness of IPTi in Southern Tanzania Phase 3
Terminated NCT00084240 - Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia Phase 2/Phase 3